Journal of Biomolecular Research & Therapeutics provide the rapid Biannually publication of articles in all areas related to biomolecules and therapeutics. Journal of Biomolecular Research & Therapeutics welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published approximately one month after acceptance.
The journal focuses on the fields of Journal of Biomolecular Research & Therapeutics which include Organic biomolecules, Biomolecular chemistry, Biomolecular structures, Biomolecular engineering, Biomolecular spectroscopy, Biomolecular modelling, Biomolecular interactions, Biomolecular techniques, Biomolecular crystellography, Biomolecular screening, NMR in Biomolecular research, Biomolecular physics, Biomolecular therapeutics, Biomolecular therapeutics companies, Enzyme-linked immunosorbent assay, Bioconjugation, BioMimetic therapeutics, Protein biosynthesis, Electroporation, Lipid therapy, Recombinant protein therapeutics, Bio-immobilization, Molecular cloning, Bioreactor, Polymer therapeutics and Smart polymers.
As a member of Publisher International linking Association, PILA, Journal of Biomolecular Research & Therapeutics (of Walsh Medical Media) follows the Creative Commons Attribution License and Scholars Open Access publishing policies.
Journal of Biomolecular Research & Therapeutics is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.
Submit your manuscript online at www.walshmedicalmedia.com/submissions/biomolecular-research-therapeutics.html or send as an e-mail attachment to the Editorial Office at [email protected]
A manuscript number will be e-mailed to the corresponding author within 72 hours.
Note: Authors are sole responsible for any scientific misconduct including plagiarism in their research articles; publisher is not responsible for any scientific misconduct happened in any published research article. As a publisher we will follow strictly scientific guidelines and EIC’s advice to retract or erratum of any article at any time if scientific misconduct or errors happened in any articles.
Walsh Medical Media Policy Regarding the NIH Mandate
Walsh Medical Media will support authors by posting the published version of articles by NIH grant-holders to PubMed Central immediately after publication.
Editorial Policies and Process
Biomolecular Research & Therapeutics follows a progressive editorial policy that encourages researchers to submit the original research, reviews and editorial observations as articles, well supported by tables and graphic representation.
Article Processing Charges (APC):
Journal of Biomolecular Research & Therapeutics is organized by Walsh Medical Media, a self supporting organization and does not receive funding from any institution/government. Hence, the operation of the Journal is solely financed by the handling fees received from authors and some academic/corporate sponsors. The handling fees are required to meet maintenance of the journal. Being an Open Access Journal, Journal of Journal of Biomolecular Research & Therapeutics does not receive payment for subscription, as the articles are freely accessible over the internet. Authors of articles are required to pay a fair handling fee for processing their articles. However, there are no submission charges. Authors are required to make payment only after their manuscript has been accepted for publication.
Average Article processing time (APT) is 55 days
In order to reduce delays, authors should assure that the level, length and format of a manuscript submission conform to Walsh Medical Media’s requirements at the submission and each revision stage. Submitted articles should have a summary/abstract, separate from the main text, of up to 300 words. This summary does not include references, numbers, abbreviations or measurements unless essential. The summary should provide a basic-level introduction to the field; a brief account of the background and principle of the work; a statement of the main conclusions; and 2-3 sentences that place the main findings into a general context. The text may contain a few short subheadings of no more than 40 characters each.
Walsh Medical Media to accomplish its vision to make scientific information & health care open access, has made a new initiation to enrich the scientific knowledge all around the world. As per the interest of the scientific community from Non-English speaking territories, we have introduced a new feature in the name of language translation. Language translation helps the scientific community to go through the articles in Chinese, Japanese and other world languages.
As we are into open access publishing and we don't receive any funds from any organization, authors who are interested to publish their paper in other languages which includes Chinese, Japanese etc., are requested to pay $ 100 along with the article processing charges.
Formats for Walsh Medical Media Contributions: Walsh Medical Media accepts the following: original articles, reviews, abstracts, addendums, announcements, article-commentaries, book reviews, rapid communications, letters to the editor, annual meeting abstracts, conference proceedings, calendars, case-reports, corrections, discussions, meeting-reports, news, obituaries, orations, product reviews, hypotheses and analyses.Our journals are all open access. Each article published by Walsh Medical Media follows a specific format.
Fast Editorial Execution and Review Process (FEE-Review Process):
Biomolecular Research & Therapeutics journal is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.
Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.
The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.
For more information on each type of article, please contact us at [email protected]
One of the authors of the article, who takes responsibility for the article during submission and peer review, should follow the instructions for submission and submit the manuscript online at Online Tracking. Please note that to facilitate rapid publication and to minimize administrative costs, Journal of Biomolecular Research & Therapeutics only accepts online submissions, and that there is an article-processing charge on all accepted manuscripts.
During submission, you will be asked to provide a cover letter, in which you should explain why your manuscript should be published in the journal and declare any potential competing interests. Please provide the contact details (name and email addresses) of two potential peer reviewers for your manuscript. These should be experts in their field who will be able to provide an objective assessment of the manuscript. The suggested peer reviewers should not have published with any of the authors of the manuscript within the past five years, should not be current collaborators and should not be members of the same research institution. Suggested reviewers will be considered along with potential reviewers recommended by the Editorial Board members.
A list of acceptable file formats appears below. Additional files of any type, such as movies, animations or original data files can also be submitted as part of the manuscript.
Here are the files required for submission :
The title page should:
Each table should be numbered and cited in sequence using Arabic numerals (i.e., Table 1, 2, 3, etc.). Titles for tables should appear above the table and be no longer than 15 words. They should be pasted at the end of the document text file, in A4 Portrait or Landscape format. These will be typeset and displayed as such in the final, published form of the article. Tables should be formatted using the ‘Table object’ in a word processing program to ensure that columns of data remain aligned when the file is sent electronically for review. Tables should not be embedded as figures or spreadsheet files. Larger datasets or tables too wide for a Landscape page can be uploaded separately, as additional files. Additional files will not be displayed in the final, laid-out PDF of the article, but a link will be provided to the files as supplied by the author.
Figures should be provided in a separate single .DOC, .PDF or .PPT file, with a resolution of at least 300 dpi and not be embedded in the main manuscript file. If a figure consists of separate parts, please submit a single, composite illustration page that includes all parts of the figure. There is no charge for the use of color figures. The figure legends should be included in the main manuscript text file at the end of the document, rather than as part of the figure file. For each figure, the following information should be provided: Figure numbers in sequence, using Arabic numerals, a title of 15 words maximum and a detailed legend of up to 300 words. Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder(s) to reproduce figures or tables that have previously been published elsewhere.
All references, including links, must be numbered consecutively, in square brackets, in the order in which they are cited in the text, and should be formatted in the National Library of Medicine style. Each reference must have an individual reference number. Please avoid excessive referencing. Only articles, datasets and abstracts that have been published or are in press, or are available through public e-print/preprint servers, may be cited. The author is responsible for obtaining permission to quote personal communications and unpublished data from cited colleagues. Journal abbreviations should follow Index Medicus/MEDLINE.
Citations in the reference list should include all named authors, up to the first 6, before adding ‘et al.’. Any in press articles cited within the references and necessary for the reviewers’ assessment of the manuscript should be made available if requested by the editorial office.
Journal of Biomolecular Research & Therapeutics only accepts manuscripts written in English. Spelling should be either U.S. English or British English, but not a mixture.
Journal of Biomolecular Research & Therapeutics will not edit submitted manuscripts for style or language; thus, reviewers may advise rejection of a manuscript due to grammatical errors. Authors are advised to write clearly and simply, and to have their article checked by colleagues before submission. In-house copyediting will be minimal. Non-native speakers of English may choose to make use of our copyediting services. Please contact [email protected] for more information. Abbreviations should be used as sparingly as possible and should be defined when first used.
For Original Articles, Methodology Articles and Reviews, there is no explicit limit on the length of papers submitted, but authors are encouraged to be concise. Commentaries and Case Reports should be between 800 and 1,500 words. Letters to the Editor should be between 1,000 and 3,000 words. There is also no restriction on the number of figures, tables, additional files or references that can be included. Figures and tables should be numbered in the order in which they are referenced in the text. Authors should include all relevant supporting data with each article.
The abstract of Original and Methodology Articles should not exceed 250 words and must be structured into Background, Methods, Results and Conclusions. For Reviews, please provide an unstructured, single paragraph summary of no more than 350 words, of the major points raised. For Commentaries and Case Reports, please provide a short, unstructured, single paragraph summary of no more than 150 words. For Letters to the Editor, please provide a short, unstructured, single paragraph summary of no more than 250 words.
Please minimize the use of abbreviations and do not cite references in the abstract. Please list your trial registration number after the abstract, if applicable.
Add a list of 3 to 10 keywords below the abstract.
The Accession Numbers of nucleic acid, protein sequences or atomic coordinates cited in the manuscript should be provided in square brackets and include the corresponding database name.
Submitted manuscripts will be evaluated initially by the editor-in-chief and an associate editor. A rapid, initial decision regarding whether to have a manuscript formally reviewed by two or more reviewers with appropriate expertise, or rejected without a formal review will be determined based on the quality, scientific rigor and data presentation/analysis of the manuscript. It is anticipated that approximately 70% of the submitted manuscripts will undergo formal review and 30% will be rejected without evaluation by external reviewers.